Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.

Ertunc D, Tok EC, Savas A, Ozturk I, Dilek S

Fertility and sterility6 Feb 2009Cited by 18 (Europe PMC)

PMID19200979DOI10.1016/j.fertnstert.2008.11.030PepBankPUB-19200979

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with PCOS and anovulatory infertility, adding ganirelix lowered serum E2 compared with FSH alone.
In plain wordsIn women with PCOS, adding ganirelix lowered serum E2 compared with FSH alone.
Peptide
Ganirelix
Outcome
DecreaseSerum E2
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Serum E(2), P, and LH levels were significantly lower in the ganirelix group.
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097901
02HumanRandomized controlled trialEfficacy outcome
In women with PCOS and anovulatory infertility, adding ganirelix lowered serum P compared with FSH alone.
In plain wordsIn women with PCOS, adding ganirelix lowered serum P compared with FSH alone.
Peptide
Ganirelix
Outcome
DecreaseSerum progesterone
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Serum E(2), P, and LH levels were significantly lower in the ganirelix group.
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097902
03HumanRandomized controlled trialEfficacy outcome
In women with PCOS and anovulatory infertility, adding ganirelix lowered serum LH compared with FSH alone.
In plain wordsIn women with PCOS, adding ganirelix lowered serum LH compared with FSH alone.
Peptide
Ganirelix
Outcome
DecreaseSerum LH
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Serum E(2), P, and LH levels were significantly lower in the ganirelix group.
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097903
04HumanRandomized controlled trialEfficacy outcome
In women with PCOS, premature luteinization occurred less often with added ganirelix than with FSH alone.
In plain wordsIn women with PCOS, premature luteinization occurred less often with added ganirelix than with FSH alone.
Peptide
Ganirelix
Outcome
DecreasePremature luteinization
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Although premature luteinization and cycle cancellation was encountered less in the ganirelix group, the pregnancy rates per cycle were similar (15.4% vs. 10.7%).
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097904
05HumanRandomized controlled trialEfficacy outcome
In women with PCOS, cycle cancellation occurred less often with added ganirelix than with FSH alone.
In plain wordsIn women with PCOS, cycle cancellation occurred less often with added ganirelix than with FSH alone.
Peptide
Ganirelix
Outcome
DecreaseCycle cancellation
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Although premature luteinization and cycle cancellation was encountered less in the ganirelix group, the pregnancy rates per cycle were similar (15.4% vs. 10.7%).
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097905
06HumanRandomized controlled trialEfficacy outcome
In women with PCOS, pregnancy rates per cycle were similar with added ganirelix and FSH alone.
In plain wordsIn women with PCOS, pregnancy rates per cycle were similar with added ganirelix and FSH alone.
Peptide
Ganirelix
Outcome
Direction not reportedPregnancy rate per cycle
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy rate per cycle
15.4%
ganirelix
Pregnancy rate per cycle
10.7%
control
Source sentences
Summary
Although premature luteinization and cycle cancellation was encountered less in the ganirelix group, the pregnancy rates per cycle were similar (15.4% vs. 10.7%).
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097906
07HumanRandomized controlled trialOther
In women with PCOS, ganirelix added 6,153 dollars per pregnancy compared with FSH alone.
In plain wordsIn women with PCOS, ganirelix added 6,153 dollars per pregnancy compared with FSH alone.
Peptide
Ganirelix
Outcome
IncreaseAdditional cost per pregnancy
Study
n = 89
Comparator
Recombinant FSH alone
Outcome group
Healthcare costs and utilization · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Additional cost per pregnancy
6153 dollars
ganirelix versus control
Source sentences
Summary
Patients would pay 6,153 dollars more for each pregnancy when using ganirelix.
5 context sentences(design, population, supporting numbers)
Summary · context
Prospective, randomized, controlled clinical study.
Summary · context
Women with PCOS and anovulatory infertility undergoing COS/IUI.
Summary · context
Recombinant FSH therapy was started on day 3.
Summary · context
In women assigned to the control group (n = 47), treatment was continued up to the day of hCG administration.
Summary · context
In patients assigned to receive GnRH antagonist (n = 42), ganirelix was added when the leading follicle was > or =14 mm.
Report a problemFND-1920097907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.